--- title: "Celldex Therap | 10-Q: FY2026 Q1 Revenue: USD 15 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/285610017.md" datetime: "2026-05-07T20:16:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285610017.md) - [en](https://longbridge.com/en/news/285610017.md) - [zh-HK](https://longbridge.com/zh-HK/news/285610017.md) --- # Celldex Therap | 10-Q: FY2026 Q1 Revenue: USD 15 K Revenue: As of FY2026 Q1, the actual value is USD 15 K. EPS: As of FY2026 Q1, the actual value is USD -1.18, missing the estimate of USD -1.163. EBIT: As of FY2026 Q1, the actual value is USD -84.44 M. ### Financial Performance for the Three Months Ended March 31, 2026, Compared with March 31, 2025 #### Revenues - **Product Development and Licensing Agreements**: Celldex Therapeutics, Inc. reported -$0 thousand in revenue for the three months ended March 31, 2026, a -100% decrease from $50 thousand for the same period in 2025. - **Contracts and Grants**: Revenue from contracts and grants decreased by -98% to $15 thousand for the three months ended March 31, 2026, from $645 thousand for the same period in 2025. - **Total Revenues**: Total revenues were $15 thousand for the three months ended March 31, 2026, down from $695 thousand in the prior year period, marking a -98% decrease. #### Operating Expenses - **Research and Development (R&D)**: R&D expenses increased by $20,387 thousand, or 39%, to $73,001 thousand for the three months ended March 31, 2026, from $52,614 thousand in the prior year. - **Barzolvolimab/Anti-KIT Program**: R&D spending on this program was $62,164 thousand in 2026, up from $39,703 thousand in 2025. - **CDX-622 Program**: R&D spending for CDX-622 was $4,294 thousand in 2026, down from $5,451 thousand in 2025. - **Other Programs**: R&D for other programs totaled $6,543 thousand in 2026, compared to $7,460 thousand in 2025. - **General and Administrative (G&A)**: G&A expenses increased by $629 thousand, or 6%, to $11,449 thousand for the three months ended March 31, 2026, from $10,820 thousand in the prior year. - **Total Operating Expenses**: Total operating expenses were $84,450 thousand for the three months ended March 31, 2026, up from $63,434 thousand in the prior year, an increase of 33%. #### Operating Loss - The operating loss increased by $21,696 thousand, or 35%, to -$84,435 thousand for the three months ended March 31, 2026, from -$62,739 thousand in the prior year. #### Investment and Other Income, Net - Investment and other income, net, decreased by $3,193 thousand, or -36%, to $5,750 thousand for the three months ended March 31, 2026, from $8,943 thousand in the prior year. #### Net Loss - The net loss increased by $24,889 thousand, or 46%, to -$78,685 thousand for the three months ended March 31, 2026, from -$53,796 thousand in the prior year. #### Cash Flow - **Net Cash Used in Operating Activities**: Net cash used in operating activities increased to -$65,588 thousand for the three months ended March 31, 2026, compared to -$54,372 thousand for the same period in 2025. - **Net Cash Provided by Investing Activities**: Net cash provided by investing activities was $72,119 thousand for the three months ended March 31, 2026, up from $42,950 thousand in the prior year. - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities increased to $327 thousand for the three months ended March 31, 2026, from $202 thousand in the prior year. - **Cash and Cash Equivalents at End of Period**: Cash and cash equivalents at the end of the period were $35,729 thousand as of March 31, 2026, compared to $17,136 thousand as of March 31, 2025. #### Liquidity and Capital Resources - As of March 31, 2026, Celldex Therapeutics, Inc. had cash, cash equivalents, and marketable securities totaling $451.5 million. These resources, combined with approximately $323.9 million in net proceeds from an April 2026 public offering, are believed to be sufficient to fund estimated working capital requirements and planned operations through 2028. #### Outlook and Strategy Celldex Therapeutics, Inc. aims to become a fully integrated, commercial-stage biopharmaceutical company focused on unmet medical needs in allergic, inflammatory, and autoimmune disorders by maximizing its technology and product portfolio through retaining full economic rights or seeking favorable commercial partnerships. The company anticipates Phase 3 data for Barzolvolimab (CDX-0159) in Chronic Spontaneous Urticaria (CSU) in Q4 2026, with a Biologics License Application (BLA) filing planned for 2027, and expects data from the Phase 1 multiple ascending dose portion of CDX-622 in Q3 2026. R&D expenses, particularly for barzolvolimab product development, and general and administrative expenses are projected to increase over the next twelve months due to expanded development and commercial planning efforts. ### Related Stocks - [CLDX.US](https://longbridge.com/en/quote/CLDX.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [BSR REIT Announces May 2026 Cash Distribution](https://longbridge.com/en/news/286615296.md)